Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Effects of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet) Therapy

NCT00110851 is registered in ClinicalTrials.gov with Wellstat Therapeutics as lead sponsor.

NCT NCT00110851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00110851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Effects of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet) Therapy
Lead sponsor
Wellstat Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2005
Completion date
August 31, 2007
Enrollment
90 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus